evipedia.ai
← Back

Enlicitide for Health & Longevity

Evidence Review created on 11/08/2026 using AI4L / Opus 5.5

Also known as: Enlicitide Decanoate, Enlicitide Chloride, MK-0616, Lipfendra

Motivation

Enlicitide (Lipfendra) is a once-daily tablet that blocks a liver protein which normally destroys the liver’s cholesterol-clearing receptors. With that protein blocked, the liver can pull more of the plaque-forming cholesterol particles out of the blood. Until now, this whole drug family was available only as injections, so a tablet form is of interest to anyone who wants deep, sustained lowering of these particles over decades.

The protein was first identified in families with inherited very high cholesterol, and people born with naturally weak versions of it were then studied as a natural experiment in lifelong cholesterol exposure. Those observations led to the injectable drugs and, later, to a search for a tablet that could reach the same target. The tablet was cleared by the American drug regulator in 2026 (Lipfendra label), while a large trial on heart attacks and strokes is still running.

This review examines what is known about enlicitide’s effects on blood fats and on heart and artery disease, its side effects and open safety questions, how it is taken, and how it fits a long-term plan to keep plaque-forming particles low for healthy aging.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary, a podcast segment, a physician update and peer-reviewed reviews that give a high-level overview of enlicitide or its drug class.

No content on enlicitide was found from Andrew Huberman, Chris Kresser, Life Extension or Lifespan.io; on-site and web searches returned nothing on this newly approved drug. Huberman Lab’s episode with Peter Attia touches PCSK9 inhibitors only in a brief chapter shared with statins (drugs that block cholesterol production) and ezetimibe, and repeats the already-listed Attia, so it is not listed. Rhonda Patrick’s item covers the drug class, not enlicitide by name.

Grokipedia

  • Enlicitide

    An encyclopedic overview of the drug’s discovery, mechanism and trial program with 29 references; its lead notes the 2026 approval, but body sections still call the drug investigational, so parts predate approval.

Examine

No Examine article on enlicitide exists. Examine.com does not typically cover prescription medications, and enlicitide is a prescription-only drug (Lipfendra label).

ConsumerLab

No ConsumerLab article on enlicitide exists. ConsumerLab does not typically cover prescription medications, and enlicitide is a prescription-only drug (Lipfendra label).

Systematic Reviews

These systematic reviews and meta-analyses pool the randomized trials of enlicitide, alone or with other oral or injectable drugs that target PCSK9.

No systematic review covers heart attacks, strokes or long-term harms with enlicitide, because no enlicitide outcome trial has reported; the principal-risk side is represented only by short-term adverse-event pooling.

Mechanism of Action

PCSK9 binds the LDL receptor (LDLR, the liver-cell protein that pulls LDL particles from the blood) and sends it for destruction inside hepatocytes (liver cells). Enlicitide, a macrocyclic peptide (a ring-shaped, stabilized amino-acid chain), binds PCSK9 and blocks this contact, so more receptors recycle and clear LDL-C (low-density lipoprotein cholesterol, the cholesterol in plaque-forming particles) (Lipfendra label). Doses of 10 mg or more cut free PCSK9 by over 90% within 0.5–1 hour (Lipfendra label). Injectable antibodies such as evolocumab block the same contact; inclisiran, a gene-silencing molecule, blocks PCSK9 production.

Key pharmacological properties:

  • Absorption: about 1% oral bioavailability (share of the dose reaching the blood), enabled by sodium caprate, a permeation enhancer (an ingredient that briefly loosens the gut lining) (Lipfendra label); dosing after a meal cuts exposure by 48% (Lipfendra label).
  • Half-life: effective about 14 hours (Lipfendra label), terminal about 244 hours (Lipfendra label); steady state (stable blood level) by about 7 days (Lipfendra label).
  • Distribution: apparent volume of distribution (how widely it spreads into tissues) 2,384 L (Lipfendra label); protein binding 32–93%, varying with concentration (Lipfendra label).
  • Metabolism: minimal, with no major metabolites (Lipfendra label); after intravenous dosing, about 73% leaves in urine (Lipfendra label); very low interaction potential through CYP (cytochrome P450, the liver’s main drug-processing enzymes) or transporters (Lipfendra label).
  • Selectivity: PCSK9 is the only target named (Lipfendra label).

A competing concern: lifelong genetic PCSK9 lowering is linked to higher fasting glucose, a possible diabetes cost (Schmidt 2017).

Historical Context & Evolution

In 2003, French researchers linked PCSK9 gene mutations to inherited very high cholesterol (Abifadel 2003). In 2006, Black participants carrying PCSK9-disabling variants showed 28% lower LDL-C (Cohen 2006) and an 88% lower risk of coronary heart disease over 15 years (Cohen 2006). These natural experiments made PCSK9 a drug target.

Injectable antibodies came first. In the FOURIER trial, funded by evolocumab’s maker Amgen, evolocumab cut LDL-C by 59% (Sabatine 2017) and reduced a composite of heart attack, stroke and related events over about 2.2 years (Sabatine 2017). Injection was seen as a barrier to convenience and acceptability, motivating a tablet, per a review co-authored by a Merck trial lead, a conflict of interest (Nguyen 2026). Merck’s oral macrocyclic peptide MK-0616 produced dose-dependent LDL-C reductions of 41–61% versus placebo at 8 weeks in a phase 2b trial co-authored by Merck employees, a manufacturer conflict of interest (Ballantyne 2023), and the US Food and Drug Administration (FDA) approved it as Lipfendra in 2026 (Lipfendra label).

Longevity-oriented physicians took interest because the genetic data suggest lifelong low LDL particle exposure protects arteries (Attia article). The cholesterol model is not unanimous: a systematic review of cohorts aged 60 or older found LDL-C inversely associated with all-cause mortality in cohorts holding 92% of participants (Ravnskov 2016), whereas trial meta-analyses show fewer vascular events per unit of LDL-C lowered (Baigent 2010). Cohorts are open to confounding (distortion by a third factor, here illness that lowers cholesterol), while trials test lowering directly; both readings remain on record.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: every enlicitide trial comes from the manufacturer’s single CORALreef program with overlapping investigators, so no independent research group has replicated the lipid findings, and no cardiovascular-event trial has reported.

Medium 🟩 🟩

Lower plaque-forming lipoproteins as add-on therapy

Added to statins, enlicitide lowers LDL-C, non-HDL-C (all cholesterol except the protective high-density lipoprotein fraction) and ApoB (apolipoprotein B, one protein per plaque-forming particle). Evidence comes from Merck-funded randomized controlled trials in people with or at risk of ASCVD (Navar 2026) and with HeFH (heterozygous familial hypercholesterolemia, an inherited high-LDL disorder) (Ballantyne 2026), plus a Merck-funded trial where it exceeded ezetimibe and bempedoic acid (Catapano 2026). An exploratory pooled analysis also found modest triglyceride lowering (Farhan 2026). The placebo-adjusted reduction was smaller at week 52 (NCT05952856).

Magnitude: LDL-C fell 55.8 percentage points more than with placebo at week 24 (95% CI −60.9 to −50.7; CI, confidence interval: the range likely to contain the true effect) (Navar 2026); in HeFH, ApoB fell 49.1 points more than with placebo (95% CI −54.0 to −44.3) (Ballantyne 2026).

Low 🟩

Fewer heart attacks and strokes

Inferred, not shown: no enlicitide outcome trial has reported. The evidence is indirect (different compound): injectable PCSK9 antibodies reduced cardiovascular events in maker-funded trials led by Sabatine (Amgen) (Sabatine 2017) and Schwartz (Sanofi, Regeneron) (Schwartz 2018). The extrapolation assumes similar LDL-C lowering brings the same event benefit.

Magnitude: With evolocumab, the primary composite endpoint occurred in 9.8% vs 11.3% with placebo, HR (hazard ratio, relative event rate over time) 0.85 (95% CI 0.79–0.92) (Sabatine 2017).

Speculative 🟨

Lower lipoprotein(a)

Enlicitide lowered Lp(a) in the CORALreef Lipids (Navar 2026) and HeFH (Ballantyne 2026) trials. Lp(a) lowering is not yet validated as reducing events, so this biomarker change has unproven clinical value.

Benefit-Modifying Factors

  • Genetic polymorphisms: People with HeFH, mostly carrying LDL-receptor mutations, had a large response (Ballantyne 2026). In homozygous familial hypercholesterolemia (FH) with no functional receptors, little benefit is expected, inferred from mechanism; enlicitide is untested there.
  • Baseline biomarkers: The fall was about 59% in HeFH participants starting near 119 mg/dL (Ballantyne 2026) and about 56% in participants starting near 96 mg/dL (Navar 2026); a fixed percentage gives larger absolute falls at higher baselines.
  • Sex: LDL-C reduction was consistent in women and men in prespecified subgroups (Ballantyne 2026; Catapano 2026).
  • Pre-existing conditions: Statin-treated adults are the tested setting. Mild-to-severe kidney impairment is expected to raise exposure only 5–26% (Lipfendra label), and moderate liver impairment does not change it (Lipfendra label).
  • Age: No overall differences in effectiveness were seen between adults 65 or older (45% of treated patients) and younger adults (Lipfendra label).
  • Dosing with food: In a Merck-authored study (a manufacturer conflict of interest), a high-fat meal 30 minutes before dosing cut exposure by about 48% (Johns 2026); model-predicted LDL-C reduction is about 59% after only a 4-hour fast (Johns 2026).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: all adverse-event data come from one manufacturer-run trial program, and no harm has been replicated by an independent research group.

Medium 🟥 🟥

No risk reaches Medium: the only adverse events exceeding placebo come from a single 303-person randomized trial (Ballantyne 2026) and were not seen in the larger placebo-controlled CORALreef Lipids trial, where adverse-reaction frequencies were similar to placebo (Lipfendra label).

Low 🟥

Diarrhea ⚠️ Conflicted

Loose stools, possibly from the sodium caprate absorption enhancer, were more common with enlicitide in the HeFH trial (Ballantyne 2026). In the larger CORALreef Lipids trial, adverse-reaction frequencies were similar to placebo (Lipfendra label). Net reading: a small single-trial signal that the larger trial did not reproduce.

Magnitude: 7.4% with enlicitide vs 2.0% with placebo, a difference of 5.4 percentage points (95% CI −0.1 to 10.3) (Ballantyne 2026).

Dizziness ⚠️ Conflicted

Dizziness was more frequent with enlicitide in the HeFH trial (Ballantyne 2026), a most common adverse reaction there per the label (Lipfendra label). In the larger CORALreef Lipids trial, adverse-reaction frequencies were similar to placebo (Lipfendra label). Net reading: an unexplained single-trial excess not seen in the larger trial.

Magnitude: 6.9% with enlicitide vs 4.0% with placebo, a difference of 3.0 percentage points (95% CI −3.4 to 8.1) (Ballantyne 2026).

New-onset diabetes ⚠️ Conflicted

Mendelian randomization (gene variants as natural experiments) links PCSK9-lowering variants to higher diabetes risk, indirectly (genes, not drug) (Schmidt 2017). Enlicitide’s HeFH trial (Ballantyne 2026) and evolocumab’s FOURIER (Sabatine 2017) showed no excess, possibly as trials span 1–2 years, not lifetimes. Net reading: trials do not support the genetic signal.

Magnitude: OR (odds ratio, the relative odds of the outcome) 1.29 (95% CI 1.11–1.50) per 1 mmol/L genetically lower LDL-C (Schmidt 2017); new or worsening diabetes in 2.0% with enlicitide vs 3.0% with placebo (Ballantyne 2026).

Speculative 🟨

Fetal harm

The label warns of possible fetal harm, inferred from cholesterol’s role in fetal development (Lipfendra label). Rat and rabbit studies showed no harm at high exposures (Lipfendra label), and human data are lacking (Lipfendra label).

Gut-lining effects of sodium caprate

Absorption enhancers transiently loosen gut-lining junctions; a safety review (McCartney 2016) notes that whether repeated daily dosing sustains this damage-repair cycle is unknown. The basis is mechanistic only.

Effects of very low LDL-C on cognition

The concern rests on cholesterol’s role in the brain; an Amgen-funded evolocumab trial (a manufacturer conflict of interest) found no cognitive difference over 19 months (Giugliano 2017). No enlicitide-specific cognitive data exist.

Risk-Modifying Factors

  • Genetic polymorphisms: Enlicitide is minimally metabolized with very low CYP involvement, so common drug-metabolism variants are not expected to alter exposure (Lipfendra label). No genetic variant is known to change its side effects.
  • Baseline biomarkers: PCSK9-lowering gene variants were linked to higher fasting glucose and diabetes risk (Schmidt 2017). Prediabetes or rising HbA1c (glycated hemoglobin, a 3-month blood-sugar average) is where such a shift would matter most, an untested inference.
  • Sex: Women who could become pregnant carry the label’s fetal-harm caution (Lipfendra label). No sex difference in adverse events has been reported.
  • Pre-existing conditions: Severe liver impairment (Child-Pugh Class C, the worst grade of a standard liver-function score) was not evaluated (Lipfendra label), and dialysis raised exposure up to 75%, judged not clinically meaningful (Lipfendra label). Chronic bowel disease is a theoretical concern with sodium caprate.
  • Age: In placebo-controlled trials, 12% of treated patients were 75 or older (Lipfendra label); no overall safety differences were seen between patients 65 or older and younger adults (Lipfendra label).

Key Interactions & Contraindications

Documented interactions:

  • Food and caloric drinks: Dosing 30 minutes after a meal reduces steady-state exposure by 48% (Lipfendra label). Mitigation: fasting dosing with water and a wait of at least 30 minutes before food or other drinks.
  • Black coffee or plain tea: No interaction found; no clinically meaningful change in exposure (Lipfendra label).
  • Statins (atorvastatin): No interaction found in either direction (Lipfendra label); combined use is the tested regimen, with enlicitide lowering LDL-C on top of statin therapy (Navar 2026).
  • Oral semaglutide: No interaction found; its absorption enhancer did not alter enlicitide exposure, and enlicitide did not alter semaglutide exposure (Lipfendra label).
  • Lithium, levothyroxine, digoxin, warfarin, alendronate, lisinopril: No interaction found; enlicitide did not change their exposure (Lipfendra label).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Other PCSK9-targeted drugs (evolocumab, alirocumab, inclisiran): Same pathway, so little added LDL-C lowering is expected, at duplicated cost. Mitigation: lipid recheck when switching.
  • Bile-acid sequestrants (gut-binding cholesterol drugs: cholestyramine, colesevelam): Binding in the gut could reduce enlicitide absorption. Mitigation: doses separated by at least 4 hours.
  • Calorie-containing supplements (fish oil, MCT (medium-chain triglyceride) oil, protein shakes): Inferred from the label’s food effect; fat or calories within 30 minutes may reduce absorption. Mitigation: intake after the 30-minute wait.
  • Over-the-counter orlistat or stimulant laxatives (bisacodyl, senna): Additive loose stools alongside enlicitide’s possible diarrhea. Mitigation: tracking of bowel habits.
  • LDL-lowering supplements (red yeast rice, berberine, plant sterols, psyllium): Additive LDL-C lowering through statin-like action, LDLR up-regulation or reduced cholesterol absorption. Mitigation: lipid recheck; red yeast rice adds statin-type muscle risk.
  • LDL apheresis (machine filtering of LDL from blood): Additive lipoprotein removal; timing relative to dosing is untested.

Populations who should avoid Enlicitide:

  • Pregnancy: The label directs discontinuation when pregnancy is recognized unless benefits outweigh fetal risk (Lipfendra label).
  • Children under 18: Safety and effectiveness not established (Lipfendra label).
  • Severe liver impairment (Child-Pugh Class C): Not evaluated (Lipfendra label).
  • Breastfeeding: No human milk data; the label asks that need be weighed against infant exposure (Lipfendra label).
  • Homozygous FH with no functional LDLR: Inferred from mechanism (no receptors to rescue); no human data for enlicitide.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Pregnancy planning: Stopping when pregnancy is recognized (Lipfendra label), with contraception or conception timing planned; mitigates possible fetal harm.
  • Glucose surveillance: HbA1c and fasting glucose at baseline and every 6–12 months; mitigates the inferred new-onset diabetes risk.
  • Bowel and dizziness tracking: Logging stool frequency and dizziness during the first 4–8 weeks, with medical review if persistent beyond 2 weeks or severe; mitigates diarrhea and dizziness.

Therapeutic Protocol

Doses below are cited; timing, titration and other parameters without a citation reflect common practice.

  • Standard dose: One 20 mg tablet once daily, the approved dose (Lipfendra label) and the dose in the pivotal phase 3 trial (Navar 2026). Phase 2b tested 6–30 mg (Ballantyne 2023).
  • Time of day: Morning, on an empty stomach, swallowed whole with water, black coffee or plain tea, with no food for 30 minutes (Lipfendra label).
  • Half-life: Effective half-life about 14 hours (Lipfendra label) and terminal half-life about 244 hours (Lipfendra label), reaching steady state in about 7 days (Lipfendra label).
  • Single vs split dose: A single daily dose (Lipfendra label); tablets are not split, crushed or chewed (Lipfendra label), and a missed dose is taken that day before food, never two doses in one day (Lipfendra label).
  • Add-on to statins (longevity practice): Peter Attia’s team calls ApoB “the true target of therapy” and highlights PCSK9 inhibition layered on aggressive statin use (Attia article).
  • Competing approaches: Injectable antibodies (evolocumab, alirocumab), twice-yearly inclisiran, or the tablets ezetimibe and bempedoic acid; enlicitide lowered LDL-C more than either tablet (Catapano 2026). Route, cost and outcome data drive the choice.
  • Genetic polymorphisms: HeFH uses the same 20 mg dose (Ballantyne 2026); no pharmacogenetic dose adjustment exists.
  • Sex: No dose adjustment; sex does not meaningfully alter exposure (Lipfendra label).
  • Age: No dose adjustment across ages 18–88 (Lipfendra label).
  • Baseline biomarkers: Baseline LDL-C, ApoB and Lp(a) set the expected absolute benefit; higher starting levels yield larger absolute reductions at the same percentage.
  • Pre-existing conditions: No adjustment for kidney impairment, including dialysis, or moderate liver impairment (Lipfendra label).

Discontinuation & Cycling

  • Lifelong intent: Enlicitide is a chronic therapy; atherosclerosis prevention depends on cumulative years of low LDL-C, so it is used long-term.
  • Withdrawal effects: No withdrawal syndrome is described in the label (Lipfendra label); LDL-C is expected to return toward baseline after stopping, inferred from mechanism.
  • Tapering: No tapering protocol exists, and none is described in the label (Lipfendra label).
  • Cycling: Not supported; benefit relies on continuous PCSK9 blockade, and LDL-C lowering persisted through 52 weeks (Ballantyne 2026).
  • Pregnancy: Stopped when pregnancy is recognized (Lipfendra label).

Sourcing and Quality

  • Single brand, prescription only: Lipfendra 20 mg tablets from Merck; no generic version is available (Drugs.com price guide).
  • Formulation matters: Oral absorption of about 1% depends on the sodium caprate formulation (Lipfendra label); compounded or “research peptide” versions cannot be assumed to absorb or work.
  • Storage: Kept in the original bottle with its desiccant (moisture absorber), tightly closed, at room temperature (Lipfendra label).
  • Inactive ingredients: Tablets contain lactose monohydrate (Lipfendra label), relevant only for rare severe lactose sensitivity.
  • Pharmacy source: Licensed pharmacies only; third-party testing and compounding pharmacies do not apply to this branded drug.

Practical Considerations

  • Time to effect: Free PCSK9 falls within hours of a dose (Lipfendra label); the phase 2b trial measured LDL-C reductions of 41–61% versus placebo at week 8 (Ballantyne 2023).
  • Common pitfalls: Taking it with breakfast, supplements or milky coffee; splitting the tablet; taking two doses after a missed day; stopping injectable therapy without rechecking lipids.
  • Regulatory status: FDA-approved in 2026 for adults with hypercholesterolemia, including HeFH, as an add-on to diet and exercise; no cardiovascular-outcome claim is approved (Lipfendra label).
  • Cost and access: About $316 cash for 30 tablets (Drugs.com price guide); a manufacturer copay card serves privately insured patients (Drugs.com price guide). Insurers may favor cheaper generic statins and ezetimibe first, a potential structural bias in coverage, guideline formation and research funding.
  • Evidence ownership: All efficacy trials are funded by Merck (MSD), the manufacturer, and several reviews are co-authored by trial investigators; independent replication is pending.

Interaction with Foundational Habits

  • Sleep: None known; no sleep-related adverse events were reported above placebo. The morning fasting dose fits naturally after the overnight fast, so sleep timing is unaffected.
  • Nutrition: Indirect and potentiating: diet changes that lower LDL-C (less saturated fat, more soluble fiber) add to the drug, which the label frames as an add-on to diet (Lipfendra label). Breakfast waits 30 minutes after dosing; time-restricted eating is compatible.
  • Exercise: None known; arthralgia (joint pain) and back pain were not more common than with placebo (Ballantyne 2026), so no statin-like muscle burden on training is expected. Exercise timing relative to the dose is unconstrained.
  • Stress management: None known; no data link enlicitide to cortisol or the stress response. A once-daily tablet removes the burden of self-injection.

Monitoring Protocol & Defining Success

Baseline testing before starting covers a lipid panel with LDL-C, non-HDL-C and ApoB, a one-time Lp(a) measurement, HbA1c and fasting glucose, and, for women who could become pregnant, a pregnancy status check. These establish the starting point against which the drug’s effect is judged and screen for the diabetes and pregnancy cautions.

Ongoing monitoring follows a cadence of a lipid panel at 4–12 weeks after starting, then every 6–12 months once stable, with HbA1c every 6–12 months. Success means a large, sustained fall in LDL-C and ApoB from the person’s own baseline, reaching the chosen target, without persistent diarrhea or dizziness. A small response at the first recheck points first to taking the tablet with food rather than to drug failure. Lp(a) is largely genetic and stable, so routine rechecks add little information.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
LDL-C <55 mg/dL very-high-risk, <70 mg/dL high-risk (ESC/EAS guideline) Expected to change; main efficacy marker ESC/EAS: European Society of Cardiology/European Atherosclerosis Society (Mach 2020); its members are cardiologists who prescribe these drugs, and a CORALreef investigator co-authored it. Conventional lab reference: <100 mg/dL. Fasting optional.
ApoB <65 mg/dL very-high-risk, <80 mg/dL high-risk (ESC/EAS guideline) Expected to change; counts plaque-forming particles Source: Mach 2020, whose ESC/EAS members prescribe these drugs, co-authored by a CORALreef investigator. Conventional lab reference varies by lab (often <100–130 mg/dL). Pair with LDL-C.
Non-HDL-C <85 mg/dL very-high-risk, <100 mg/dL high-risk (ESC/EAS guideline) Expected to change; captures all plaque-forming cholesterol Source: Mach 2020, whose ESC/EAS members prescribe these drugs, co-authored by a CORALreef investigator. Conventional lab reference: <130 mg/dL. Calculated as total minus HDL cholesterol.
Lp(a) No established target; track change from own baseline Expected to change modestly (about 25% lower, Mulligan 2026) Measure once at baseline; Mach 2020 (ESC/EAS, whose members prescribe these drugs) flags >180 mg/dL (>430 nmol/L) as very high inherited risk. Largely genetic and stable.
HbA1c <5.7% (standard reference range) Safety check; rising values prompt review Pair with fasting glucose; addresses the genetic diabetes signal (Schmidt 2017). No fasting needed.

Qualitative markers:

  • Stool frequency and consistency, especially in the first weeks
  • Episodes of dizziness or lightheadedness
  • Consistency of fasting morning dosing (missed or food-adjacent doses)
  • Energy and exercise tolerance compared with any prior statin experience

Emerging Research

  • CORALreef Outcomes (NCT06008756): Phase 3, about 14,550 high-risk adults; primary endpoint coronary death, heart attack, clot-related stroke, blocked leg blood flow or urgent artery-reopening procedures; estimated primary completion 2029. A positive result would show event reduction directly; a null result would undercut the LDL-based case.
  • CORALreef Extension (NCT06492291): Phase 3 open-label (unblinded) extension of about 3,000 participants; primary endpoints adverse events and discontinuations through 2028. Clean multi-year safety would strengthen lifelong use; new diabetes or gut signals would weaken it.
  • Rosuvastatin combination, MK-0616-037 (NCT07216482): Phase 3 factorial trial (each drug alone and together) of 996 adults testing enlicitide with rosuvastatin; estimated completion of November 5, 2026 has passed, status active, not recruiting, no results posted. A positive result would support a two-tablet first-line regimen; a null result would favor statin-first sequencing.
  • Lp(a) combination (NCT07614984): Phase 2, about 750 adults with Lp(a) ≥150 nmol/L, testing oral MK-7262 with enlicitide; estimated completion 2027. A positive result would enable all-oral LDL-C and Lp(a) lowering; a null result would leave Lp(a) largely untreated.
  • Pediatric HeFH (NCT07058077): Phase 2/3, about 153 children and adolescents; estimated completion 2037. A positive result would support starting in youth; a null or unsafe result would restrict use to adults.
  • Competing oral PCSK9 agents: Laroprovstat, a small molecule blocking PCSK9-driven receptor degradation, is in phase 3, per a review (Nguyen 2026); head-to-head data could reposition enlicitide.
  • Diabetes question: Genetic data predict a diabetes cost of PCSK9 inhibition (Schmidt 2017); multi-year enlicitide glucose data could confirm or retire this concern.
  • Independent replication: Reviews note the evidence comes from short-term trials of lipid outcomes (Khattak 2026); independent, longer trials could strengthen or weaken the case.

Conclusion

Enlicitide is the first tablet that blocks the liver protein which normally destroys the liver’s cholesterol-clearing receptors, a target until now reached only by injection. For people pursuing very low levels of plaque-forming cholesterol particles over decades, it offers a daily tablet that, in a year of trials, produced large and lasting falls in these particles on top of standard cholesterol drugs.

The main limit is what has not yet been shown. No trial has reported whether enlicitide itself prevents heart attacks or strokes; that expectation rests on the injected drugs that share its target and on the broad link between fewer cholesterol particles and fewer artery events. A large trial on these events is still running.

Reported side effects were few: loose stools and dizziness appeared more often than with an inactive comparison tablet in one smaller trial but not in the larger one. Gene studies raise a question about blood sugar that trial data so far do not support, and the effects of decades of use on the gut lining and in pregnancy remain unknown.

Its effect depends on being swallowed on an empty stomach with a wait before eating; lapses weaken it.

The evidence base is young, and the maker funded every trial, with several of the same researchers writing the reviews, so no independent group has yet confirmed the findings. The picture is strong for lowering cholesterol particles and uncertain for long-term outcomes and rare harms.

Top - Benefits - Risks - Protocol